EcoDrugPlus

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSCMIG00000010883
Gene Symbol: PPARG
4 Cross references
407 Possible Orthologues:

Phosphatidylinositol 4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma Isoform-Like

Ensembl ID : ENSCMIG00000001819
Gene Symbol: LOC103175665
4 Cross references
214 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSCMIG00000002435
Gene Symbol: PIK3CA
4 Cross references
275 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSCMIG00000017010
Gene Symbol: PIK3CB
3 Cross references
218 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta

Ensembl ID : ENSCMIG00000005191
Gene Symbol: PIK3CD
3 Cross references
214 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSCMIG00000003988
Gene Symbol: PDE10A
3 Cross references
207 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSCMIG00000011763
Gene Symbol: PDE3A
3 Cross references
258 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSCMIG00000014449
Gene Symbol: PDE3B
4 Cross references
204 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSCMIG00000005800
Gene Symbol: PDE4A
3 Cross references
250 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSCMIG00000019281
Gene Symbol: PDE4D
3 Cross references
235 Possible Orthologues:

Phosphodiesterase 5a

Ensembl ID : ENSCMIG00000003211
Gene Symbol: PDE5A
4 Cross references
210 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSCMIG00000000208
Gene Symbol: PDE7A
4 Cross references
241 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).